Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo

Current Biology

Volumn 7, Issue 11, 1997, Pages 860-869

  Böttger, Angelika ^a   Böttger, Volker ^a   Sparks, Alison ^a   Liu, Wei Li ^a   Howard, Stephanie F ^a   Lane, David P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 0031282325     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(06)00374-5     Document Type: Article

References (30)

1. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR: High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 1995,5:931-936.
2. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
3. Maki CG, Huibregtse JM, Howley PM: In vivou biquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996, 56:2649-2654.
4. Chen CY, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB: Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 1994, 91:2684-2688.
5. Finlay CA: The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993, 13:301-306.
6. Otto A, Deppert W : Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53. Oncogene 1993, 8:2591-2603.
7. Barak Y, Juven T, Haffner R, Oren M: Mdm2 expression is induced by wild type p53 activity. EMBO J 1993, 12:461-468.
8. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993, 7:1126-1132.
9. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
10. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362:857-860.
11. Jones SN, Roe AE, Donehower LA, Bradley A: Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378:206-208.
12. Montes de Oca Luna R, Wagner DS, Lozano G: Rescue of early embryonic lethality in Mdm2-deficient mice by deletion of p53. Nature 1995, 378:203-206.
13. Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
14. Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
15. Böttger A, Böttger V, Garcia Echeverria C, Chene P, Hochkeppel HK, Sampson W, et al.: Molecular characterization of the hdm2-p53 interaction. J Mol Biol 1997, 269:744-756.
16. Böttger V, Böttger A, Howard SF, Picksley SM, Chene P, Garcia Echeverria C, Hochkeppel HK, Lane DP: Identification of novel Mdm2 binding peptides by phage display. Oncogene 1996, 13:2141-2147.
17. LaVallie ER, DiBlasio EA, Kovacic S, Grant KL, Schendel PF, McCoy JM, Green MR: Athioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. How different eukaryotic transcriptional activators can cooperate promiscuously. Biotechnology 1993, 11:187-193.
18. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274:948-953.
19. Blaydes JP, Gire V, Rowson JM, Wynford-Thomas D: Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene 1997, 14:1859-1868.
20. Florenes VA, Maelandsmo GM, Forus A, Andreassen, A, Myklebost O, Fodstad O: MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer lnst 1994, 86:1297-1302.
21. Landers JE, Haines DS, Strauss JFR, George DL: Enhanced translation: a novel mechanism of Mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994, 9:2745-2750.
22. Hupp TR, Sparks A, Lane DP: Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995, 83:237-245.
23. Lu X, Lane DP: Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993, 75:765-778.
24. Vojtesek B, Lane DP: Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 1993, 105:607-612.
25. Renzing J, Lane DP: p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts. Oncogene 1995, 10:1865-1868.
26. Siegel J, Fritsche M, Mai S, Brandner G, Hess RD: Enhanced p53 activity and accumulation in response to DNA damage upon DNA transfection. Oncogene 1995, 11:1363-1370.
27. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R: Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 1996, 380:548-550.
28. Juven T, Barak Y, Zauberman A, George DL, Oren M: Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the Mdm2 gene. Oncogene 1993, 8:3411-3416.
29. Picksley SM, Vojtesek B, Sparks A, Lane DP: Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994, 9:2523-2529.
30. Lin YS, Green MR: Similarities between prokaryotic and eukaryotic cyclic AMP-responsive promoter elements. Nature 1989, 340:656-659.